Latest & greatest articles for lamotrigine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lamotrigine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lamotrigine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lamotrigine

1. Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures. (Abstract)

Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures. This is an update of the Cochrane Review first published in 2010; it includes one additional study. Primary generalised tonic-clonic seizures are a type of generalised seizure. Other types of seizures include: absence, myoclonic, and atonic seizures. Effective control of tonic-clonic seizures reduces the risk of injury and death, and improves quality of life. While most people achieve seizure control with one (...) antiepileptic drug, around 30% do not, and require a combination of antiepileptic drugs.To assess the effectiveness and tolerability of add-on lamotrigine for drug-resistant primary generalised tonic-clonic seizures.For the latest update, we searched these databases on 19 March 2019: Cochrane Register of Studies (CRS) Web, MEDLINE Ovid, and the WHO International Clinical Trials Registry Platform (ICTRP). The CRS includes records from the Cochrane Epilepsy Group Specialized Register, CENTRAL, Embase

2020 Cochrane

2. Lamotrigine augmentation in treatment-resistant unipolar depression: A comprehensive meta-analysis of efficacy and safety. (Abstract)

Lamotrigine augmentation in treatment-resistant unipolar depression: A comprehensive meta-analysis of efficacy and safety. Augmentation strategies are commonly applied when an individual is unresponsive to antidepressant monotherapy. Lamotrigine is currently considered at best only as second line augmentation for treatment-resistant unipolar depression while its clinical efficacy and safety profiles remain inconclusive. We intended to assess the therapeutic effects and safety profiles (...) of lamotrigine augmentation in patients with treatment-resistant unipolar depression by conducting a meta-analysis.MEDLINE, Embase, EBSCO, Cochrane, Web of Science, Scopus, Wanfang and Ariniti databases were searched. Coprimary outcomes, including changes in severity of depression and response rate, were measured in this study. Secondary outcomes were defined as the safety profile of the intervention, including reported discontinuation rate and adverse events.Eight double-blinded randomized controlled trials

2020 Journal of psychopharmacology (Oxford, England)

3. Lamotrigine add-on therapy for drug-resistant focal epilepsy. (Abstract)

Lamotrigine add-on therapy for drug-resistant focal epilepsy. This is an updated version of the Cochrane Review previously published in 2016. Epilepsy is a common neurological disorder, affecting 0.5% to 1% of the population. For nearly 30% of these people, their epilepsy is resistant to currently available drugs. Pharmacological treatment remains the first choice to control epilepsy. Lamotrigine is one of the newer antiepileptic drugs. Lamotrigine, in combination with other antiepileptic drugs (...) (add-on), can reduce seizures, but with some adverse effects.To determine the effects of lamotrigine on (1) seizures, (2) adverse-effect profile, and (3) cognition and quality of life, compared to placebo, when used as an add-on treatment for people with drug-resistant focal epilepsy.For the latest update of the review, we searched the following databases on 9 March 2020: Cochrane Register of Studies (CRS Web), MEDLINE (Ovid, 1946 to March 06, 2020). CRS Web includes randomized or quasi-randomized

2020 Cochrane

4. Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. (Full text)

Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. Whether patients with adult bipolar disorder (BD) who have been clinically stabilized with lithium or lamotrigine should continue this medication is not established fully. This systematic review and meta-analysis evaluated the efficacy and safety (...) of lithium and lamotrigine for maintenance treatment in clinically stable patients with adult BD.This meta-analysis included only double-blind, randomized, placebo-controlled trials with an enrichment design that selected patients who responded acutely to lithium or lamotrigine. Reports prior to November 15, 2018, were retrieved from the PubMed/Cochrane Library/Embase. The primary outcome was the relapse rate due to any mood episode at the study endpoint. Other outcomes were relapse rates due to a manic

2020 Neuropsychopharmacology reports PubMed abstract

5. The efficacy and safety of lamotrigine for absence seizures in children and adolescents: A systematic review and meta-analysis. (Abstract)

The efficacy and safety of lamotrigine for absence seizures in children and adolescents: A systematic review and meta-analysis. This systematic review and meta-analysis of randomized controlled trials (RCTs) systematically explored the effectiveness and safety of lamotrigine for absence seizures in children and adolescents.Keywords searches were conducted in Pubmed Embase Cochrane Central Register of Controlled Trials Wanfang CNKI from inception through March 2019. The RCTs comparing (...) lamotrigine with other drugs and/or placebo for the treatment of absence seizures in children and adolescents were considered in this study. The study was conducted adhering to PRISMA guidelines.Eight RCTs (n = 787) were included in our study. Among these studies, one study (N = 45 patients) used placebo as a control and seven studies (N = 742 patients) used positive drug controls. For effectiveness, there was significant difference between lamotrigine and valproate [OR = 0.42, 95%CI (0.28-0.63), I2 = 0

2020 Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

6. Meta-analysis of the Influence of UGT Genetic Polymorphisms on Lamotrigine Concentration. (Full text)

Meta-analysis of the Influence of UGT Genetic Polymorphisms on Lamotrigine Concentration. Uridine 5'-diphospho-glucuronosyltransferases (UGTs) are involved in the metabolism of lamotrigine, but whether the UGT1A4 and UGT2B7 genetic polymorphisms affect lamotrigine concentration remains controversial. Thus, the objective of this meta-analysis was to analyse the influence of UGT1A4 and UGT2B7 genetic polymorphisms on lamotrigine concentration. Through searching, screening, selection, data (...) extraction and quantitative analyses, the influence of UGT1A4 and UGT2B7 genetic polymorphisms on lamotrigine concentration-to-dose ratio (CDR) was assessed by meta-analysis of nine studies. Neither UGT1A4 70C>A nor 142T>G significantly affected lamotrigine CDR values (standardized difference in means [SDM] = 0.433, 95% confidence interval [CI] = -0.380-1.302; SDM = -0.458, 95% CI = -1.141-0.224, respectively). Only the UGT2B7 -161C>T homozygous variant had significantly higher CDR values than the wild

2019 Basic & clinical pharmacology & toxicology PubMed abstract

7. [Relationship between UGT1A4 142T>G polymorphism and serum concentration of lamotrigine in Chinese epileptic patients: a meta-analysis]. (Abstract)

[Relationship between UGT1A4 142T>G polymorphism and serum concentration of lamotrigine in Chinese epileptic patients: a meta-analysis]. Objective: To investigate the relationship between the polymorphism of Uridine diphosphate glucuronosyltransferases (UGT)1A4 142T>G (*3, L48V, rs 2011425)and serum concentration of lamotrigine(LTG) in Chinese epileptic patients. Methods: Databases including Cochrane Library, PubMed, Embase, CNKI, VIP and Wanfang were searched for the studies (...) -administration in Chinese epileptic pediatric patients and those children with wild-type (TT genotype) have a tendency to have a lower serum concentration of lamotrigine.

2019 Zhonghua yi xue za zhi

8. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. (Full text)

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. This is an updated version of the Cochrane Review previously published in 2017.Absence seizures (AS) are brief epileptic seizures which present in childhood and adolescence. Depending on clinical features and electroencephalogram (EEG) findings they are divided into typical, atypical absences, and absences with special features. Typical absences are characterised by sudden loss of awareness (...) and an EEG typically shows generalised spike wave discharges at three cycles per second. Ethosuximide, valproate and lamotrigine are currently used to treat absence seizures. This review aims to determine the best choice of antiepileptic drug for children and adolescents with AS.To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures (AS), when compared with placebo or each other.For the latest update we searched

2019 Cochrane PubMed abstract

9. Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: A meta-analysis. (Full text)

Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: A meta-analysis. The aim of this study was to assess the association between human leukocyte antigen (HLA) variants and lamotrigine (LTG)-induced cutaneous adverse drug reactions (cARDs).A comprehensive literature search was conducted on the relationship of HLA alleles with LTG-induced cADRs in Asian populations, through PubMed, Embase, and Cochrane Library. The last search

2018 Seizure PubMed abstract

10. Lamotrigine

Lamotrigine Top results for lamotrigine - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lamotrigine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

11. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. (Full text)

Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. This is an updated version of the original Cochrane Review published in Issue 11, 2006 of the Cochrane Database of Systematic Reviews.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment up to 70% of individuals with active epilepsy have the potential to become (...) seizure-free, and to go into long-term remission shortly after starting drug therapy with a single antiepileptic drug (AED) in monotherapy.The correct choice of first-line AED for individuals with newly diagnosed seizures is of great importance. It is important that the choice of AEDs for an individual is made using the highest quality evidence regarding the potential benefits and harms of the various treatments.Carbamazepine or lamotrigine are recommended as first-line treatments for new onset focal

2018 Cochrane PubMed abstract

12. Bipolar disorder: Lamotrigine

Bipolar disorder: Lamotrigine Lamotrigine | Prescribing information | Bipolar disorder | CKS | NICE Search CKS… Menu Lamotrigine Bipolar disorder: Lamotrigine Last revised in June 2019 Lamotrigine Contraindications and cautions Prescribe lamotrigine with caution to people with: Myoclonic seizures (may be exacerbated). Parkinson’s disease (may be exacerbated). [ ] What are the adverse effects of lamotrigine? Adverse effects of lamotrigine include: Skin rash : All people (adults and children (...) ) who develop a rash should be promptly evaluated and lamotrigine withdrawn immediately unless the rash is clearly not drug related. Rash has been reported in up to 12% of people taking lamotrigine in clinical trials . These rashes were maculopapular in appearance, generally appeared within 8 weeks of starting treatment, and resolved on withdrawal of lamotrigine. Serious, potentially life threatening skin rashes, including Stevens–Johnson syndrome, toxic epidermal necrolysis and drug reaction

2018 NICE Clinical Knowledge Summaries

13. Lamotrigine-induced sexual dysfunction and non-adherence: case analysis with literature review (Full text)

Lamotrigine-induced sexual dysfunction and non-adherence: case analysis with literature review Optimal anti-epileptic drug (AED) treatment maximises therapeutic response and minimises adverse effects (AEs). Key to therapeutic AED treatment is adherence. Non-adherence is often related to severity of AEs. Frequently, patients do not spontaneously report, and clinicians do not specifically query, critical AEs that lead to non-adherence, including sexual dysfunction. Sexual dysfunction prevalence (...) in patients with epilepsy ranges from 40 to 70%, often related to AEDs, epilepsy or mood states. This case reports lamotrigine-induced sexual dysfunction leading to periodic non-adherence.To report lamotrigine-induced sexual dysfunction leading to periodic lamotrigine non-adherence in the context of multiple comorbidities and concurrent antidepressant and antihypertensive pharmacotherapy.Case analysis with PubMed literature review.A 56-year-old male patient with major depression, panic disorder without

2017 BJPsych open PubMed abstract

14. Acute lamotrigine overdose: a systematic review of published adult and pediatric cases. (Abstract)

Acute lamotrigine overdose: a systematic review of published adult and pediatric cases. Lamotrigine is a broad-spectrum anticonvulsant commonly used to treat seizure and bipolar mood disorders. Evidence from case series and retrospective studies indicate that lamotrigine overdose is usually benign. However, there are reported cases of cardiac arrest and mortality following lamotrigine overdose. We undertook a systematic review of the literature on lamotrigine overdoses to better understand (...) the clinical severity, the relevance of serum concentrations, and therapeutic interventions for overdose.To characterize manifestations of acute lamotrigine overdose, determine if serum concentrations predict poisoning severity, and evaluate the effectiveness of overdose management interventions.We performed a literature search across eight databases, including Medline, EMBASE, and the Cochrane Library, from database inception to April 2014. Major bibliographic databases were updated on 31 May 2017

2017 Clinical toxicology (Philadelphia, Pa.)

15. Lamotrigine versus valproic acid monotherapy for generalised epilepsy: A meta-analysis of comparative studies. (Full text)

Lamotrigine versus valproic acid monotherapy for generalised epilepsy: A meta-analysis of comparative studies. The standard for generalized epilepsies (GE) monotherapy in treatment is valproic acid (VPA) and lamotrigine (LTG) has been proposed as an alternative to VPA. This study aimed to evaluate the safety and efficacy of LTG on GE seizure in comparison with VPA.A search was conducted based on the databases from Pubmed, Embase and the Cochran database up to February 2017. The relative risk

2017 Seizure PubMed abstract

16. Effectiveness of amitriptyline and lamotrigine in neuropathic pain after traumatic spinal cord injuries (Full text)

Effectiveness of amitriptyline and lamotrigine in neuropathic pain after traumatic spinal cord injuries 28546871 2018 11 13 2058-6124 3 2017 Spinal cord series and cases Spinal Cord Ser Cases Effectiveness of amitriptyline and lamotrigine in neuropathic pain after traumatic spinal cord injuries. 16036 10.1038/scsandc.2016.36 Almeida Rodrigo L RL Department of Spinal Cord Injury/SARAH Rehabilitation Hospital Network/SARAH Brasilia, Brasilia, Distrito Federal, Brazil. Beraldo Paulo S PS

2017 Spinal cord series and cases PubMed abstract

17. Erratum to: Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. (Full text)

Erratum to: Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. 28512694 2019 11 20 1179-1934 31 6 2017 06 CNS drugs CNS Drugs Erratum to: Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. 451 10.1007/s40263-017-0439-7 Pariente Gali G Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada

2017 CNS drugs PubMed abstract

18. Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. (Abstract)

Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. Lamotrigine is used in pregnancy to control epilepsy and mood disorders. The reproductive safety of this widely used drug remains undefined and may represent a significant public health concern.We aimed to perform a systematic review and meta-analysis of existing knowledge related to malformation rates and maternal-neonatal outcomes after in utero exposure to monotherapy (...) with lamotrigine.Relevant studies were identified through systematic searches conducted in MEDLINE (Ovid), Embase (Ovid), CENTRAL (Ovid), and Web of Science (Thomson Reuters) from database inception to July 2016; no language or date restrictions were applied. All publications of clinically relevant outcomes of pregnancies following in utero exposure to lamotrigine were included in this systematic review and meta-analysis.A total of 21 studies describing immediate pregnancy outcomes and rates of congenital malformations

2017 CNS drugs

19. Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials. (Full text)

Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials. Lamotrigine is an antiepileptic drug used for the treatment of epilepsy, bipolar disorder and numerous off-label uses. The development of rash significantly affects its use. The most concerning of these adverse reactions is Stevens-Johnson syndrome/toxic epidermal necrolysis. We performed a systematic review (...) of randomized controlled trials using lamotrigine as a monotherapy to quantify the incidence of cutaneous reactions, particularly Stevens-Johnson syndrome/toxic epidermal necrolysis. Of a total of 4,364 papers regarding lamotrigine, 122 studies met our inclusion and exclusion criteria. In total, 18,698 patients were included with 1,570 (8.3%) of patients experiencing an adverse dermatologic reaction. The incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis was 0.04%.

2017 Anais brasileiros de dermatologia PubMed abstract

20. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. (Full text)

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. This is an updated version of the original Cochrane review originally published in 2003, Issue 3, and updated in 2005, Issue 4.Absence seizures are brief epileptic seizures which present in childhood and adolescence. Depending on clinical features and electroencephalogram (EEG) findings they are divided into typical, atypical absences, and absences with special features. Typical absences (...) are characterised by sudden loss of awareness and an EEG typically shows generalised spike wave discharges at three cycles per second. Ethosuximide, valproate and lamotrigine are currently used to treat absence seizures. This review aims to determine the best choice of antiepileptic drug for children and adolescents with typical absence seizures.To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures, when compared

2017 Cochrane PubMed abstract